Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies

Henriette Farkas,Zsuzsanna Balla

DOI: https://doi.org/10.1080/13543784.2024.2320700

2024-02-26

Expert Opinion on Investigational Drugs

Abstract:Introduction Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent edema and predominantly caused by the dysregulation of the kinin-kallikrein system.

pharmacology & pharmacy

What problem does this paper attempt to address?

Recent advances in the discovery and development of drugs targeting the kallikrein-kinin system

Petra Wisniewski,Tanja Gangnus,Bjoern B. Burckhardt

DOI: https://doi.org/10.1186/s12967-024-05216-5

IF: 8.44

2024-04-27

Journal of Translational Medicine

Abstract:The kallikrein-kinin system is a key regulatory cascade involved in blood pressure maintenance, hemostasis, inflammation and renal function. Currently, approved drugs remain limited to the rare disease hereditary angioedema. However, growing interest in this system is indicated by an increasing number of promising drug candidates for further indications.

medicine, research & experimental
The Future of Therapeutic Options for Hereditary Angioedema

Tukisa D. Smith,Marc A. Riedl

DOI: https://doi.org/10.1016/j.anai.2024.04.029

2024-04-29

Abstract:Hereditary angioedema (HAE) is a rare, genetic condition causing unpredictable and severe episodes of angioedema that are debilitating and life-threatening. HAE can be classified into HAE due to C1INH deficiency (HAE-C1INH), or HAE with normal C1INH (HAE-nl-C1INH). HAE-C1INH is subcategorized as type I and II based upon deficient or dysfunctional circulating C1INH protein resulting from inherited or spontaneous mutations in the SERPING1 gene leading to uncontrolled Factor XII(FXII)/plasma kallikrein activation and excessive bradykinin production. Bradykinin-2 receptor activation leads to vasodilation, increased vascular permeability and smooth muscle contractions, resulting in subcutaneous or submucosal fluid extravasation that can affect the face, extremities, airway, gastrointestinal and genitourinary systems. HAE-nl-C1INH is caused by either a known or unknown genetic mutation and the mechanisms are less well-established but most forms are thought to be related to bradykinin signaling with a similar presentation as HAE-C1INH despite normal levels of C1INH protein and function. Current HAE management strategies include on-demand and prophylactic treatments which replace C1INH, reduce kallikrein activity or block bradykinin binding to the bradykinin B2 receptor (BDKRB2). With the advent of additional small molecule inhibitors, monoclonal antibodies, RNA-targeted therapies, gene therapies and gene modification approaches, preclinical studies and human clinical trials are underway to further expand therapeutic options in HAE. This review article will briefly summarize current HAE treatments and provide an overview of potential future therapies for HAE.

immunology,allergy
A transcriptomics study of hereditary angioedema attacks

Giuseppe Castellano,Chiara Divella,Fabio Sallustio,Vincenzo Montinaro,Claudia Curci,Andrea Zanichelli,Erika Bonanni,Chiara Suffritti,Sonia Caccia,Fleur Bossi,Anna Gallone,Francesco Paolo Schena,Loreto Gesualdo,Marco Cicardi

DOI: https://doi.org/10.1016/j.jaci.2018.03.016

Abstract:Background: Hereditary angioedema (HAE) caused by C1-inhibitor deficiency is a lifelong illness characterized by recurrent acute attacks of localized skin or mucosal edema. Activation of the kallikrein/bradykinin pathway at the endothelial cell level has a relevant pathogenetic role in acute HAE attacks. Moreover, other pathways are involved given the variable clinical expression of the disease in different patients. Objective: We sought to explore the involvement of other putative genes in edema formation. Methods: We performed a PBMC microarray gene expression analysis on RNA isolated from patients with HAE during an acute attack and compared them with the transcriptomic profile of the same patients in the remission phase. Results: Gene expression analysis identified 23 genes significantly modulated during acute attacks that are involved primarily in the natural killer cell signaling and leukocyte extravasation signaling pathways. Gene set enrichment analysis showed a significant activation of relevant biological processes, such as response to external stimuli and protein processing (q < 0.05), suggesting involvement of PBMCs during acute HAE attacks. Upregulation of 2 genes, those encoding adrenomedullin and cellular receptor for urokinase plasminogen activator (uPAR), which occurs during an acute attack, was confirmed in PBMCs of 20 additional patients with HAE by using real-time PCR. Finally, in vitro studies demonstrated the involvement of uPAR in the generation of bradykinin and endothelial leakage. Conclusions: Our study demonstrates the increase in levels of adrenomedullin and uPAR in PBMCs during an acute HAE attack. Activation of these genes usually involved in regulation of vascular tone and in inflammatory response might have a pathogenic role by amplifying bradykinin production and edema formation in patients with HAE.
A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema

Dan Sexton,Ryan Faucette,Melody Rivera-Hernandez,Jon A Kenniston,Nikolaos Papaioannou,Janja Cosic,Kris Kopacz,Gary Salmon,Chantal Beauchemin,Salomé Juethner,Dave Yeung

DOI: https://doi.org/10.3389/falgy.2024.1436855

2024-09-17

Abstract:Background: Cleaved high-molecular-weight kininogen (HKa) is a disease state biomarker of kallikrein-kinin system (KKS) activation in patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-C1INH), the endogenous inhibitor of plasma kallikrein (PKa). Objective: Develop an HKa-specific enzyme-linked immunosorbent assay (ELISA) to monitor KKS activation in the plasma of HAE-C1INH patients. Methods: A novel HKa-specific antibody was discovered by antibody phage display and used as a capture reagent to develop an HKa-specific ELISA. Results: Specific HKa detection following KKS activation was observed in plasma from healthy controls but not in prekallikrein-, high-molecular-weight kininogen-, or coagulation factor XII (FXII)-deficient plasma. HKa levels in plasma collected from HAE-C1INH patients in a disease quiescent state were higher than in plasma from healthy controls and increased further in HAE-C1INH plasma collected during an angioedema attack. The specificity of the assay for PKa-mediated HKa generation in minimally diluted plasma activated with exogenous FXIIa was demonstrated using a specific monoclonal antibody inhibitor (lanadelumab, IC50 = 0.044 µM). Conclusions: An ELISA was developed for the specific and quantitative detection of HKa in human plasma to support HAE-C1INH drug development. Improved quantification of the HKa biomarker may facilitate further pathophysiologic insight into HAE-C1INH and other diseases mediated by a dysregulated KKS and may enable the design of highly potent inhibitors targeting this pathway.
Clinical Progress in Hepatic Targeting for Novel Prophylactic Therapies in Hereditary Angioedema

Marc A Riedl,Laura Bordone,Alexey Revenko,Kenneth B Newman,Danny M Cohn

DOI: https://doi.org/10.1016/j.jaip.2023.12.025

Abstract:Hereditary angioedema (HAE) is typically caused by a deficiency of the protease inhibitor C1 inhibitor (C1INH). The absence of C1INH activity on plasma kallikrein and factor XIIa leads to overproduction of the vasoactive peptide bradykinin, with resulting angioedema. As the primary site of C1INH and prekallikrein production, the liver is recognized as an important therapeutic target in HAE, leading to the development of hepatic-focused treatment strategies such as GalNAc-conjugated antisense technology and gene modification. This report reviews currently available data on hepatic-focused interventions for HAE that have advanced into human trials. Donidalorsen is an investigational GalNAc3-conjugated antisense oligonucleotide that binds to prekallikrein mRNA in the liver and reduces the expression of prekallikrein. Phase 2 data with subcutaneous donidalorsen demonstrated a significant reduction in HAE attack rate compared with placebo. Phase 3 trials are underway. ADX-324 is a GalNAc3-conjugated short-interfering RNA being investigated in HAE. BMN 331 is an investigational AAV5-based gene therapy vector that expresses wild-type human C1INH and is targeted to hepatocytes. A single intravenous dose of BMN 331 is intended to replace the defective SERPING1 gene and enable patients to produce functional C1INH. A first-in-human phase 1/2 study is ongoing with BMN 331. NTLA-2002 is an investigational in vivo clustered regularly interspaced short palindromic repeats/Cas9-based therapy designed to knock out the prekallikrein-coding KLKB1 gene in hepatocytes; a phase 1/2 study is ongoing. Findings from these and other ongoing studies are highly anticipated with the expectation of expanding the array of treatment options in HAE.
Clinical features and potential markers of disease in idiopathic non-histaminergic angioedema, a real-life study

Ilaria Mormile,Maria Celeste Gigliotti,Anne Lise Ferrara,Roberta Gatti,Giuseppe Spadaro,Amato de Paulis,Stefania Loffredo,Maria Bova,Angelica Petraroli

DOI: https://doi.org/10.1007/s12026-024-09501-9

2024-06-07

Immunologic Research

Abstract:Idiopathic non-histaminergic acquired angioedema (InH-AAE) is a rare disease, with unknown etiology and pathogenesis, characterized by recurrent clinical manifestations and resistance to antihistamines and corticosteroids. We aim to evaluate clinical features and potential markers of disease in an Italian cohort of patients with InH-AAE. We enrolled 26 patients diagnosed with InH-AAE. Information about clinical features, treatments, routine laboratory investigations, immunological and genetic tests were collected. We assessed plasma levels of complement components, angiogenic and lymphangiogenic mediators, proinflammatory cytokines and chemokines, and activity of phospholipases A2. Finally, patients underwent nailfold videocapillaroscopy (NVC); both quantitative and qualitative capillaroscopic parameters were analyzed. Plasma levels of VEGFs were similar in healthy controls and in InH-AAE patients. ANGPT1 was decreased in InH-AAE patients compared to controls while ANGPT2 was similar to controls. Interestingly, the ANGPT2/ANGPT1 ratio (an index of vascular permeability) was increased in InH-AAE patients compared to controls. sPLA2 activity, elevated in patients with C1-INH-HAE, showed differences also when measured in InH-AAE patients. TNF-α concentration was higher in InH-AAE patients than in healthy controls, conversely, the levels of CXCL8, and IL-6 were similar in both groups. At the NVC, the capillary loops mainly appeared short and tortuous in InH-AAE patients. InH-AAE represents a diagnostic challenge. Due to the potential life-threatening character of this condition, a prompt identification of the potentially bradykinin-mediated forms is crucial. A better comprehension of the mechanism involved in InH-AAE would also lead to the development of new therapeutic approaches to improve life quality of patients affected by this disabling disease.

immunology
CRISPR-Based Therapy for Hereditary Angioedema

Danny M Cohn,Padmalal Gurugama,Markus Magerl,Constance H Katelaris,David Launay,Laurence Bouillet,Remy S Petersen,Karen Lindsay,Emel Aygören-Pürsün,David Maag,James S Butler,Mrinal Y Shah,Adele Golden,Yuanxin Xu,Ahmed M Abdelhady,David Lebwohl,Hilary J Longhurst

DOI: https://doi.org/10.1056/NEJMoa2405734

2024-10-24

Abstract:Background: Hereditary angioedema is a rare genetic disease characterized by severe and unpredictable swelling attacks. NTLA-2002 is an in vivo gene-editing therapy that is based on clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9. NTLA-2002 targets the gene encoding kallikrein B1 (KLKB1). A single dose of NTLA-2002 may provide lifelong control of angioedema attacks. Methods: In this phase 2 portion of a phase 1-2 trial, we randomly assigned adults with hereditary angioedema in a 2:2:1 ratio to receive NTLA-2002 in a single dose of 25 mg or 50 mg or placebo. The primary end point was the number of angioedema attacks per month (the monthly attack rate) from week 1 through week 16. Secondary end points included safety, pharmacokinetics, and pharmacodynamics (i.e., the change from baseline in total plasma kallikrein protein level); exploratory end points included patient-reported outcomes. Results: Of the 27 patients who underwent randomization, 10 received 25 mg of NTLA-2002, 11 received 50 mg, and 6 received placebo. From week 1 through week 16, the estimated mean monthly attack rate was 0.70 (95% confidence interval [CI], 0.25 to 1.98) with 25 mg of NTLA-2002, 0.65 (95% CI, 0.24 to 1.76) with 50 mg, and 2.82 (95% CI, 0.80 to 9.89) with placebo; the difference in the estimated mean attack rate with NTLA-2002 as compared with placebo was -75% with 25 mg and -77% with 50 mg. Among patients who received NTLA-2002, 4 of the 10 patients who received 25 mg (40%) and 8 of the 11 who received 50 mg (73%) were attack-free with no additional treatment during the period from week 1 through week 16. The most common adverse events among patients who received NTLA-2002 were headache, fatigue, and nasopharyngitis. The mean percent change in total plasma kallikrein protein levels from baseline to week 16 was -55% with 25 mg and -86% with 50 mg; levels remained unchanged with placebo. Conclusions: NTLA-2002 administered in a single dose of 25 mg or 50 mg reduced angioedema attacks and led to robust and sustained reduction in total plasma kallikrein levels in patients with hereditary angioedema. These results support continued investigation in a larger phase 3 trial. (Funded by Intellia Therapeutics; ClinicalTrials.gov number, NCT05120830; EudraCT number, 2021-001693-33.).
Pathophysiology and underlying mechanisms in Hereditary Angioedema

Alberto López Lera

DOI: https://doi.org/10.4274/balkanmedj.galenos.2020.2020.10.166

2020-11-18

Balkan Medical Journal

Abstract:This review aims to summarize the main pathophysiological events involved in the development of hereditary angioedema (OMIM#106100). Hereditary angioedema is a rare genetic disease inherited in an autosomal dominant manner and caused by a loss of control over the plasma contact system or kallikrein-kinin system, which results in unrestrained bradykinin generation or signaling. In patients with hereditary angioedema, BK binding to endothelial cells leads to recurrent episodes of swelling at subcutaneous or submucosal tissues that can be life threatening when affecting the upper respiratory tract. The disease can either present with hypocomplementemia owing to the presence of pathogenic variants in the gene encoding complement C1 inhibitor (hereditary angioedema with C1-inhibitor deficiency) or present with normocomplementemia and associate with elevated estrogen levels owing to gain-of-function variants in the genes encoding coagulation proteins involved in the kallikrein-kinin system (namely, coagulation FXII [FXII-associated hereditary angioedema], plasminogen [PLG-associated hereditary angioedema], and high-molecular-weight kininogen [KNG1-associated hereditary angioedema]). Moreover, in recent years, novel pathogenic variants have been described in the genes encoding angiopoietin 1 (ANGPT1-associated hereditary angioedema) and myoferlin (MYOF-associated hereditary angioedema), which further expand the pathophysiological picture of hereditary angioedema.

medicine, general & internal
Contact System Activation and Bradykinin Generation in Angioedema: Laboratory Assessment and Biomarker Utilization

Sandra C Christiansen,Bruce L Zuraw

DOI: https://doi.org/10.1016/j.iac.2024.03.011

Abstract:The role of contact system activation has been clearly established in the pathogenesis of hereditary angioedema due to C1 inhibitor deficiency (HAE-C1INH). C1 inhibitor (C1INH)-protease complexes, levels of functional C1INH, plasma kallikrein activation, and cleavage of high-molecular-weight kininogen have each been associated with disease activity. More recently, HAE with normal levels of C1INH (HAE-nl-C1INH) has been recognized. Six genetic mutations have been identified which are linked to HAE-nl-C1INH phenotypes. The majority of individuals with HAE-nl-C1INH fall into the unknown category. There is substantial evidence that bradykinin generation underlies the recurrent attacks of swelling in some of these cohorts.
Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada

Adil Adatia,Jean-Nicolas Boursiquot,Dawn Goodyear,Chrystyna Kalicinsky,Amin Kanani,Susan Waserman,Michelle M. L. Nguyen,Abhinav Wadhwa,Jessica Weiss,Ahmed El-Zoeiby,Stephen Betschel

DOI: https://doi.org/10.1186/s13223-024-00910-x

2024-09-28

Allergy Asthma & Clinical Immunology

Abstract:Hereditary angioedema with normal C1-inhibitor function (HAE nC1-INH) and idiopathic angioedema of unknown etiology (AE-UNK) are rare conditions that cause recurrent subcutaneous and submucosal swelling. The characteristics and clinical outcomes of patients with these conditions in Canada have not been studied.

immunology,allergy
Advent of oral medications for the treatment of hereditary angioedema

Anna Valerieva,Teresa Caballero,Markus Magerl,Joao P Frade,Paul K Audhya,Timothy Craig

DOI: https://doi.org/10.1002/clt2.12391

Abstract:Background: Hereditary angioedema (HAE) is a rare genetic disorder characterized by unpredictable, debilitating episodes of submucosal and/or subcutaneous tissue swelling, which may be life-threatening depending on anatomic location. The two primary management strategies for HAE are ready access to effective on-demand treatment in all patients and the prevention of attacks (short-term prophylaxis [STP] and long-term prophylaxis [LTP]) in appropriate patients. All approved on-demand and most LTP medications require subcutaneous or intravenous administration. Injection-related challenges include trypanophobia (fear of needles), difficulty with self-administration, injection-site reactions (e.g., pain, erythema, bleeding, bruising), and anxiety-all contributing to poor compliance and administration delays. Oral HAE treatments may improve outcomes by reducing treatment barriers. Aim: To review oral therapies, approved or in development, for on-demand treatment and/or prevention of HAE attacks. Materials and methods: To provide a comprehensive review, data was obtained from publicly available resources through a targeted PubMed literature review and supplemented by information provided on company websites (search cutoff of May 31, 2024). Results: Berotralstat, an oral plasma kallikrein (PKa) inhibitor, is approved for LTP. Sebetralstat, another PKa inhibitor, is the investigational first oral on-demand HAE treatment to complete a phase 3 trial. Deucrictibant, an oral bradykinin B2 receptor antagonist, has completed phase 2 trials for on-demand therapy and LTP. Several other oral PKa inhibitors (ATN249, VE-4666, and VE-4062) are in early development for LTP. Conclusion: Substantial advances have been made in the development of oral treatments for HAE. These treatments have the potential to improve and optimize clinical outcomes, satisfaction, and quality of life among patients with HAE.
Unveiling the Complexities of Hereditary Angioedema

Cristina Violeta Tutunaru,Oana Maria Ică,George G. Mitroi,Carmen Daniela Neagoe,George F. Mitroi,Olguța Anca Orzan,Beatrice Bălăceanu-Gurău,Simona Laura Ianoși

DOI: https://doi.org/10.3390/biom14101298

IF: 6.064

2024-10-15

Biomolecules

Abstract:Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic disorder, constituting approximately 2% of all clinical cases of angioedema, with a global prevalence estimated between 1 in 50,000 and 1 in 150,000 individuals. The condition affects individuals of all genders and ethnic backgrounds without significant variation. HAE is classified into three types. Type I HAE, which accounts for 85% of cases, is characterized by a deficiency of the C1 esterase inhibitor (C1-INH) gene. Type II HAE, making up 15% of cases, involves a dysfunctional C1-INH. Type III HAE, which represents about 5% to 10% of cases, is often estrogen-dependent and although several mutations have been identified, it typically involves normal C1-INH activity. Despite the differences in C1-INH functionality, all three types of HAE manifest with similar clinical symptoms. HAE leads to recurrent episodes of non-pruritic angioedema, which occurs in the absence of urticaria. Breakthroughs in understanding HAE pathophysiology have revolutionized treatment, leading to the development of highly targeted therapies for both acute management and long-term prevention. Meanwhile, cutting-edge advancements in omics technologies are unlocking new possibilities for biomarker discovery, paving the way for more precise diagnoses and personalized treatment strategies that could significantly enhance patient outcomes. This review will delve into the intricate pathophysiology, diverse clinical presentations, and diagnostic challenges of HAE while exploring emerging biomarkers and innovative approaches to therapeutic management and prevention strategies. Additionally, it will underscore the vital importance of screening family members of affected individuals, even when symptoms are not present.

biochemistry & molecular biology
Control of Hereditary Angioedema

Chen Wang

DOI: https://doi.org/10.1056/nejmc2032164

IF: 158.5

2021-02-04

New England Journal of Medicine

Abstract:To the Editor: Cohn et al. (Sept. 24 issue)1 report the outcomes of the compassionate use of antisense oligonucleotide (IONIS-PKK) targeting prekallikrein to control severe bradykinin-mediated angi...

medicine, general & internal
Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene Variants

François Marceau,Arnaud Bonnefoy,Isabelle Boccon-Gibod,Laurence Bouillet,Matthieu Picard,Ghislain Levesque,Hannah Laure Elfassy,Hélène Bachelard,Jacques Hébert,Konrad Bork,Georges E. Rivard,Julie M. Gauthier,Karen E. Binkley

DOI: https://doi.org/10.3389/fmed.2020.00358

IF: 3.9

2020-07-17

Frontiers in Medicine

Abstract:Bradykinin (BK)-mediated angioedema (AE) states are rare acquired or hereditary conditions involving localized edema of the subcutaneous and submucosal tissues. Citrated plasma from healthy volunteers or patients with hereditary angioedema (HAE) with normal level of C1-inhibitor (C1-INH) was used to investigate pathways of BK formation and breakdown relevant to AE physiopathology. The half-life of BK (100 nM) added to normal plasma was 34 s, a value that was increased ~12-fold when the angiotensin converting enzyme (ACE) inhibitor enalaprilat (130 nM) was added (enzyme immunoassay measurements). The BK half-life was similarly increased ~5-fold following 2 daily oral doses of enalapril maleate in healthy volunteers, finding of possible relevance for the most common form of drug-associated AE. We also addressed the kinetics of immunoreactive BK (iBK) formation and decline, spontaneous or under three standardized stimuli: tissue kallikrein (KLK-1), the particulate material Kontact-APTT™ and tissue plasminogen activator (tPA). Relative to controls, iBK production was rapid (10-20 min) and very intense in response to tPA in plasma of female heterozygotes for variants in gene F12 coding for factor XII (FXII) (p.Thr328Lys, 9 patients; p.Thr328Arg, one). An increased response to Kontact-APTT™ and an early tPA-induced cleavage of anomalous FXII (immunoblots) were also observed. Biotechnological inhibitors showed that the early response to tPA was dependent on plasmin, FXIIa and plasma kallikrein. Results from post-menopausal and pre-menopausal women with HAE-FXII were indistinguishable. The iBK production profiles in seven patients with the plasminogen p.Lys330Glu variant (HAE-PLG) did not significantly differ from those of controls, except for an unexpected, rapid and lanadelumab-resistant potentiation of KLK-1 effect. This enzyme did not cleave plasminogen or factor XII, suggesting a possible idiosyncratic interaction of the plasminogen pathogenic variant with KLK-1 activity. KLK-1 abounds in salivary glands and human saliva, hypothetically correlating with the clinical presentation of HAE-PLG that includes the swelling of the tongue, lips and contiguous throat tissues. Samples from HAE patients with normal C1-INH levels and F12 gene did not produce excessive iBK in response to stimuli. The ex vivo approach provides physiopathological insight into AE states and supports the heterogeneous physiopathology of HAE with normal C1-INH.

medicine, general & internal
Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study

William R Lumry,Jonathan A Bernstein,H Henry Li,Andrew J MacGinnitie,Marc Riedl,Daniel F Soteres,Timothy J Craig,Marilyn Campion,Ryan Iarrobino,Leslie E Stolz,William E Pullman

DOI: https://doi.org/10.2500/aap.2013.34.3653

Abstract:Hereditary angioedema (HAE) is a rare disorder characterized by recurrent attacks of potentially life-threatening edema. The plasma kallikrein inhibitor ecallantide is approved for treatment of acute HAE attacks. This study evaluates the efficacy and safety of ecallantide for treatment of multiple HAE episodes in the DX-88/19 (continuation) study. Patients received 30 mg of subcutaneous ecallantide for acute HAE attack symptoms, with no limit on number of episodes treated. Primary end point was change in patient-reported mean symptom complex severity (MSCS) score at 4 hours. Additional end points included change in MSCS score at 24 hours, treatment outcome score (TOS) at 4 and 24 hours, and time to response. Safety parameters included adverse events. Statistical analyses were conducted on qualifying treatment episodes (those with ≥12 patients). One hundred forty-seven patients received treatment for 625 episodes; analyses were conducted through 13 treatment episodes. Across 13 episodes at 4 hours, mean change in MSCS score ranged from -1.04 to -1.36, and mean TOSs ranged from 56.2 to 79.8. Median time to onset of sustained improvement ranged from 59 to 113 minutes. There was no indication of reduced efficacy with repeated ecallantide use. No new safety signals were detected. Eight patients (5.4%) reported potential hypersensitivity reactions, six of whom met the definition of anaphylaxis based on National Institute of Allergy and Infectious Diseases criteria. Ecallantide is effective for acute recurrent HAE attacks and maintains its efficacy and safety during multiple treatment episodes in patients with HAE. Potential hypersensitivity reactions were consistent with prior reports.
Hereditary Angioedema: Diagnosis, Clinical Implications, and Pathophysiology

Evan S Sinnathamby,Peter P Issa,Logan Roberts,Haley Norwood,Kevin Malone,Harshitha Vemulapalli,Shahab Ahmadzadeh,Elyse M Cornett,Sahar Shekoohi,Alan D Kaye

DOI: https://doi.org/10.1007/s12325-022-02401-0

Abstract:Hereditary angioedema (HAE) is an autosomal dominant disorder caused by a mutation in the C1 esterase inhibitor gene. HAE affects 1/50,000 people worldwide. Three main types of HAE exist: type I, type II, and type III. Type I is characterized by a deficiency in C1-INH. C1-INH is important in the coagulation complement, contact systems, and fibrinolysis. Most HAE cases are type I. Type I and II HAE result from a mutation in the SERPING1 gene, which encodes C1-INH. Formally known as type III HAE is typically an estrogen-dependent or hereditary angioedema with normal C1-INH activity. Current guidelines now recommend subdividing hereditary angioedema with normal C1 esterase inhibitor gene (HAE-nl-C1-INH formerly known as HAE type III) based on underlying mutations such as in kininogen-1 (HAE-KNG1), plasminogen gene (PLG-HAE), myoferlin gene mutation (MYOF-HAE), heparan sulfate-glucosamine 3-sulfotransferase 6 (HS3ST6), mutation in Hageman factor (factor XII), and in angiopoietin-1 (HAE-ANGPT-1). The clinical presentation of HAE varies between patients, but it usually presents with nonpitting angioedema and occasionally abdominal pain. Young children are typically asymptomatic. Those affected by HAE usually present with symptoms in their early 20s. Symptoms can arise as a result of stress, infection, or trauma. Laboratory testing shows abnormal levels of C1-INH and high levels of bradykinin. C4 and D-dimer levels can also be monitored if an acute HAE attack is suspected. Acute treatment of HAE can include IV infusions of C1-INH, receptor antagonists, and kallikrein inhibitors. Short- and long-term prophylaxis can also be administered to patients with HAE. First-line therapies for long-term prophylaxis also include IV infusion of C1-INH. This review aims to thoroughly understand HAE, its clinical presentation, and how to treat it.
Targeting factor XIIa for therapeutic interference with hereditary angioedema

Danny M. Cohn,Thomas Renné

DOI: https://doi.org/10.1111/joim.20008

2024-09-19

Journal of Internal Medicine

Abstract:Abstract Hereditary angioedema (HAE) is a rare, potentially life‐threatening genetic disorder characterized by recurrent attacks of swelling. Local vasodilation and vascular leakage are stimulated by the vasoactive peptide bradykinin, which is excessively produced due to dysregulation of the activated factor XII (FXIIa)‐driven kallikrein–kinin system. There is a need for novel treatments for HAE that provide greater efficacy, improved quality of life, minimal adverse effects, and reduced treatment burden over current first‐line therapies. FXIIa is emerging as an attractive therapeutic target for interference with HAE attacks. In this review, we draw on preclinical, experimental animal, and in vitro studies, providing an overview on targeting FXIIa as the basis for pharmacologic interference in HAE. We highlight that there is a range of FXIIa inhibitors in development for different therapeutic areas. Of these, garadacimab, an FXIIa‐targeted inhibitory monoclonal antibody, is the most advanced and has shown potential as a novel long‐term prophylactic treatment for patients with HAE in clinical trials. The evidence from these trials is summarized and discussed, and we propose areas for future research where targeting FXIIa may have therapeutic potential beyond HAE.

medicine, general & internal
Urticaria and Angioedema: Understanding Complex Pathomechanisms to Facilitate Patient Communication, Disease Management, and Future Treatment

George N Konstantinou,Marc A Riedl,Peter Valent,Indrashis Podder,Marcus Maurer

DOI: https://doi.org/10.1016/j.jaip.2022.11.006

Abstract:Chronic spontaneous urticaria (CSU) is primarily a T2-dominant disease with a complex genetic background. Skin mast cell activation can be induced not only via the IgE-FcεRI axis but also from several other distinct mechanisms, molecules, and receptors involved in CSU onset, persistence, and exacerbation. These include autoallergy, autoimmunity, central or peripheral neuroimmune dysregulation, activation of both extrinsic and intrinsic coagulation pathways, and microbial infections. Besides mast cells, recent reports suggest the active and direct involvement of basophils and eosinophils. Several biological characteristics or biomarkers have been linked with CSU's known endotypes and may help forecast therapeutic responses. The introduction of biologic therapy for CSU has been a major advance in the last 10 years. The cornerstone of angioedema (AE) pathogenesis is increased vascular permeability and plasma leakage into the deeper dermis and subcutis, either mediated by histamine or bradykinin (BK). C1-inhibitor deficiency, hereditary or acquired, is the primary cause of BK-mediated AE due to increased plasma BK concentration. Other complex conditions have been identified, with some likely involving contact system dysregulation and other putative mechanisms related to vascular endothelial dysfunction. The approval of multiple hereditary-AE-specific therapies for both prevention and acute attacks has revolutionized treatment of this disease. Any new knowledge of the pathogenesis of CSU and AE offers the opportunity to improve patient information, physician-patient communication, prediction of therapeutic responses, selection of precise tailor-made treatment for each patient, and exploration of novel treatment options for those who do not achieve disease control with current medications.
Etiology, Recent Advances, and Clinical Trials Data for the Treatment of Angioedema: A Review

Mukul Nishad,Sushma Verma,Ramish Maqsood,Rashmi Saxena Pal

DOI: https://doi.org/10.2174/0115748871307432240930051749

2024-10-11

Abstract:Angioedema is a health issue that affects parts of the body like the upper pulmonary and gastric pathways and is identified by abrupt, nonpitting enlargement of the skin, mucous membranes, or both. The swelling usually lasts a few hours to 72 hours and may appear as non-puritic, subcutaneous, or submucosal organ edema. It is characterized by localized swelling brought on by the release of histamine. Itching is rare, and usual areas of appearance include the hands, feet, face, and genitalia, with periorbital swelling being the most often. The main objective of this review article is to study in brief the classifications, etiology, pathophysiology, and clinical trial data by describing the recent advancement in the treatment of angioedema. Various research articles obtained from different journals indexed under Scopus and SCI were used to prepare the review article and for illustrative work software such as Biorender and Microsoft Word was used. Histamine-- mediated angioedema, linked to allergic reactions, coexists with urticaria. Bradykinin-mediated angioedema, exemplified by hereditary angioedema and acquired forms, lacks urticaria. Idiopathic angioedema, with uncertain etiology. Imitated angioedema results from non-IgE-mediated reactions, often induced by medications. It is a complicated medical condition with a variety of causes and mechanisms. Over time, outcomes for patients have been greatly improved by a growing understanding of its etiology, pathophysiology, and available treatments. The field of medical treatment for this difficult problem is always changing, and this is partly due to clinical trials.
Clinical Experience with Berotralstat in Patients with Hereditary Angioedema with Normal C1-Esterase Inhibitor: A Commented Case Series

Henry Kanarek,Drew Mutschelknaus

DOI: https://doi.org/10.2147/jaa.s445893

2024-02-23

Journal of Asthma and Allergy

Abstract:Henry J Kanarek, &ast Drew Austin Saville Mutschelknaus &ast Kanarek Allergy, Asthma & Immunology, Leawood, KS, USA &astThese authors contributed equally to this work Correspondence: Henry J Kanarek, Tel +1 (913) 451-8555, Fax +1 (913) 327-8553, Email Hereditary angioedema (HAE) is a rare genetic disorder characterized by potentially life-threatening episodes of swelling. Most HAE cases are caused by deficient (type I) or dysfunctional (type II) C1-esterase inhibitor (C1-INH) protein. However, some patients present with a subtype of HAE that is associated with normal plasma levels of functional C1-INH protein and complement component 4 (HAE-nC1INH). Treatment of HAE-nC1INH is driven by clinical experience as robust clinical trial data to inform treatment decisions are lacking in this population. This retrospective case series assessed clinical features and treatment outcomes in 15 patients with HAE-nC1INH who initiated long-term prophylaxis with oral berotralstat 150 mg once daily as part of their disease management pathway. Most patients were female (93%), with a median age of 49 years. All patients experienced abdominal swelling attacks. On average, patients tried a mean of 4 different treatments for their HAE, including berotralstat. Although most patients associated prophylactic and on-demand medications that target the bradykinin pathway with improvements in the frequency and/or severity of attacks, treatment outcomes varied considerably between patients, highlighting the importance of a personalized approach to disease management. In this case series, berotralstat was an effective prophylactic treatment option in most patients with HAE-nC1INH. Further studies are required to demonstrate the potential efficacy, safety, and impact on quality of life of currently approved HAE therapies in patients with HAE-nC1INH. Keywords: hereditary angioedema, normal C1-esterase inhibitor, prophylaxis, berotralstat, lanadelumab, plasma-derived C1-esterase inhibitor, abortive therapy Patients with hereditary angioedema (HAE) experience unpredictable and potentially life-threatening recurrent episodes of swelling that generally affect the extremities, genitals, abdomen, larynx, and face. 1–3 Some patients present with a form of HAE with normal C1-inhibitor (HAE-nC1INH), which is associated with normal plasma levels of functional C1-inhibitor (C1-INH) protein and complement component 4 (C4). 3 Mutations in genes such as coagulation factor XII (FXII), plasminogen, angiopoietin 1, kininogen 1, heparan sulfate glucosamine 3-O-sulfotransferase-6, and myoferlin have been identified in several patients with HAE-nC1INH. Some of these genes are involved with the production of bradykinin. However, the prevalence and pathophysiology of the disease are less clear than in HAE with low serum level or functional deficiency in C1 inhibitor (HAE-C1INH), and the etiology of the disease remains unknown for many patients. 1,4–9 Additionally, HAE-nC1INH is more challenging to definitively diagnose than HAE-C1INH because diagnosis reliant on genetic testing only identifies a small subset of patients with the disease. 8,10 Additionally, these genetic tests are not readily available in all clinical practices. 1 Overall, the swelling attacks experienced by patients with HAE-nC1INH and patients with HAE-C1INH are similar, but subtle differences exist between them 1,7 Patients with HAE-nC1INH typically present with their first symptoms of disease in late adolescence to early adulthood, while the first symptoms of HAE-C1INH typically appear in childhood. 1,5,11 Furthermore, patients with symptomatic HAE-nC1INH are predominately female, with exposure to estrogens frequently linked to the onset and exacerbation of swelling attacks. 4,5,12–14 Edema of the face, tongue, and oropharynx have been documented more frequently in patients with HAE-nC1INH than in patients with HAE-C1INH. 1,6,7,15,16 A review of 57 French patients with confirmed FXII mutations indicated that 74% of patients experienced HAE attacks affecting the ear, nose, and throat, while 80% experienced abdominal attacks 13 despite some experts suggesting that patients with HAE-nC1INH typically have fewer abdominal symptoms. 1 The occurrence of non-specific presenting symptoms in patients with HAE-nC1INH often results in misdiagnosis, ongoing treatment with inappropriate therapy (ie, antihistamines, corticosteroids, adrenaline) and/or unnecessary procedures (ie, surgical intervention). 5,17–19 Furthermore, the absence of robust data from clinical trials evaluating HAE therapies in patients with HAE-nC1INH means that, once diagnosis is suspected, the treatment of this patient population is based on clinical expe -Abstract Truncated-

immunology,allergy,respiratory system

Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies

Recent advances in the discovery and development of drugs targeting the kallikrein-kinin system

The Future of Therapeutic Options for Hereditary Angioedema

A transcriptomics study of hereditary angioedema attacks

A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema

Clinical Progress in Hepatic Targeting for Novel Prophylactic Therapies in Hereditary Angioedema

Clinical features and potential markers of disease in idiopathic non-histaminergic angioedema, a real-life study

CRISPR-Based Therapy for Hereditary Angioedema

Pathophysiology and underlying mechanisms in Hereditary Angioedema

Contact System Activation and Bradykinin Generation in Angioedema: Laboratory Assessment and Biomarker Utilization

Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada

Advent of oral medications for the treatment of hereditary angioedema

Unveiling the Complexities of Hereditary Angioedema

Control of Hereditary Angioedema

Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene Variants

Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study

Hereditary Angioedema: Diagnosis, Clinical Implications, and Pathophysiology

Targeting factor XIIa for therapeutic interference with hereditary angioedema

Urticaria and Angioedema: Understanding Complex Pathomechanisms to Facilitate Patient Communication, Disease Management, and Future Treatment

Etiology, Recent Advances, and Clinical Trials Data for the Treatment of Angioedema: A Review

Clinical Experience with Berotralstat in Patients with Hereditary Angioedema with Normal C1-Esterase Inhibitor: A Commented Case Series